Reviewer Comment on Randall et al. “Calcitonin Gene-Related Peptide Inhibitor Use in 2018–2023: A Retrospective Cohort Study Across Six Canadian Provinces”
Published online by Cambridge University Press:
20 January 2026
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
Article purchase
Temporarily unavailable
References
1
Tepper, SJ.History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment. Headache J Head Face Pain. 2018;58:238–275.10.1111/head.13379CrossRefGoogle Scholar
2
Medrea, I, Cooper, P, Langman, M, et al. Updated Canadian Headache Society Migraine Prevention Guideline with Systematic Review and Meta-analysis. Can J Neurol Sci. 2024;7:1–23.Google Scholar
3
Randall, JR, Martins, KJB, Luu, H, et al. Calcitonin gene-related peptide inhibitor use in 2018-2023: a retrospective cohort study across six Canadian provinces. Can J Neurol Sci. 2025:1–26.10.1017/cjn.2025.10506CrossRefGoogle ScholarPubMed
4
Hepp, Z, Dodick, DW, Varon, SF, Gillard, P, Hansen, RN, Devine, EB.Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35:478–488.10.1177/0333102414547138CrossRefGoogle ScholarPubMed
5
Hepp, Z, Dodick, DW, Varon, SF, et al.Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37:470–485.10.1177/0333102416678382CrossRefGoogle Scholar
Target article
Calcitonin Gene-Related Peptide Inhibitor Use in 2018–2023: A Retrospective Cohort Study Across Six Canadian Provinces
Related commentaries (1)
Reviewer Comment on Randall et al. “Calcitonin Gene-Related Peptide Inhibitor Use in 2018–2023: A Retrospective Cohort Study Across Six Canadian Provinces”